“But the Heart Doctor Said”…Optimizing Medication Management in Heart Failure Nearing Life’s End

This recorded webinar includes review of the oldies, but goodies, and new agents on the market for management of heart failure and consideration for use of these agents at the end of life, debunking some of the myths that preclude use of guideline directed medical therapy.

Target Audience

Hospice Medical Directors
HPM Physicians
Nurses
Nurse Practitioners
Pharmacists
PAs 

Learning Outcomes

Desired Learning Outcomes: 
Through an interactive case-based approach, participants will self-report the ability to apply, analyze and evaluate:

  • when/if chronic heart failure medications should be deprescribed based on the potential clinical benefit(s) of use.
  • hemodynamic and/or side effects that should be taken into consideration when assessing the appropriateness guideline-directed medical therapies.
  • attainable and realistic goals of care.
  • treatment & monitoring plans for symptom management.

Activity topics include:

  1. Hemodynamics of heart failure and medication impact 
  2. Addressing new drug therapies and deprescribing heart failure meds in advanced illness
  3. Defining clinical success
  4. Practical tips for use of drug therapy 
Activity summary
Activity Published: 
09/21/2022
Activity Expires: 
10/28/2025
Member cost:
$39.00
List Price:
$49.00
Part of: 
AAHPM Learn Subscription
Rating: 
0

AAHPM endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for disclosure and commercial support and endeavors to ensure balance, independence, objectivity, and scientific rigor for all accredited products or programs. All who are in a position to control or influence the content of an educational activity must disclose any relevant financial relationships with ineligible companies. *Disclosure documents were reviewed for potential conflicts of interest and, if identified, were resolved prior to confirmation of participation. Only those who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.
All editors, faculty and staff have disclosed no relevant financial relationships.
*An ineligible company is defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. 

Faculty
Raya Kheirbek, MD MPH
Alexandra McPherson, PharmD MPH 
Mary Lynn McPherson, PharmD MA MDE BCPS FAAHPM
Diana Violanti, PharmD BCPS
Kristin Watson, PharmD BCCP

Staff
Stephanie Adams
Julie Bruno, MSW LCSW
Leah Farfan
Theresa Nissen
Julie Tanner, BSN RN-BC CHPN
Angie Tryfonopoulos

This recorded activity is a non-accredited learning resource. No CME or MOC is offered with this activity.

Price

Member cost:
$39.00
List Price:
$49.00
Please login or register to take this course.